admin, Author at Généthon - Page 5 of 10

Genethon is delighted about the launch of a gene therapy clinical trial for late-onset Pompe disease

February 3, 2021

Genethon gets the green light from the ANSM to start an innovative gene therapy trial for Duchenne muscular dystrophy

December 2, 2020

Genethon welcomes the submission to EMA of Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)

September 21, 2020

A Genethon team succeeds in inhibiting the immune response linked to AAV, opening up the possibility of treating more patients by gene therapy

June 10, 2020

Genethon welcomes the conclusive results of a gene therapy trial in Chronic Septic Granulomatosis, a rare disease of the immune system

January 30, 2020

Genethon strengthens its collaboration with Sarepta Therapeutics for the development of the gene therapy product GNT0004 in Duchenne muscular dystrophy

January 9, 2020

A gene therapy based clinical trial for Fanconi anemia patients offers its first successful results

September 9, 2019

First in vivo proof-of-concept in Steinert’s myotonic dystrophy, a neuromuscular disease

June 26, 2019

Towards a clinical trial for gamma-sarcoglycanopathy, limb-girdle muscular dystrophy

May 24, 2019

Clinical Proof-of-Concept Data for OTL-102 for the Treatment of X-CGD

February 25, 2019